May 22, 2026 | Read online

Coverage is Now Live: See Why (TLSA) Just Jumped On to Our Screen

Any content you receive is for information purposes only. Always conduct your own research.

*Sponsored

Market Maven Insights Puts Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) On Tomorrow’s Watchlist—Friday, May 22, 2026

Don’t miss the next breakout — get real-time alerts sent straight to your phone!

Full Coverage On (TLSA) Starts Now

(TLSA) Just Hit Our Radar—Take A Quick Look Right Now…

May 22, 2026

Coverage is Now Live: See Why (TLSA) Just Jumped On to Our Screen

Dear Reader,

A little-known neuroinflammation story is suddenly starting to accelerate.

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) just announced that it has fully enrolled its randomized, double-blind, placebo-controlled Phase 2a study evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS).

The milestone represents the first placebo-controlled Phase 2 trial for intranasal foralumab and positions the company for expected topline data in late Q3 2026, with another potential visibility event already scheduled for the ACTRIMS-ECTRIMS meeting in Toronto this October.

The market quickly appeared to take notice.

(TLSA) reached as high as $1.84 during yesterday’s session, marking an approximate 14% intraday move while also triggering multiple bullish indicators across TradingView’s technical analysis dashboard.

At the same time, momentum surrounding the broader neuroinflammation space has continued building as people search for differentiated approaches targeting conditions tied to MS, ALS, Parkinson’s-like syndromes, and other degenerative disorders.

That is where the story around intranasal foralumab begins to stand out.

The company’s lead candidate is currently the only fully human anti-CD3 monoclonal antibody in clinical development, with ongoing research tied to major institutions including Harvard, Yale, and Johns Hopkins.

Meanwhile, analyst coverage has also continued shifting higher.

On May 19, 2026, Lucid Capital Markets analyst Elemer Piros, PhD, reiterated a Bullish rating on (TLSA) while increasing his 12-month target from $8 to $9.

With shares recently around the $1.50 range, that target sits notably above recent levels.

Technical momentum has also remained constructive, with Barchart data showing (TLSA) continuing to trend above its 5, 20, 50, and 100-day moving averages.

Add in two separate clinical updates released within the past week, and the setup around (TLSA) has become increasingly difficult to ignore.

Here’s why the company has moved toward the top of our watchlist today—Friday, May 22, 2026.

Why Tiziana Life Sciences Ltd. (Nasdaq: TLSA) Is Starting To Draw Attention

Tiziana Life Sciences is a clinical-stage biotechnology company developing immune-focused therapies targeting neurodegenerative and inflammatory disorders. Its lead program, intranasal foralumab, is being advanced as a differentiated non-invasive immunotherapy designed to stimulate regulatory T cells through nasal administration.

The company’s approach is currently being evaluated across multiple neurological indications, with ongoing research and clinical activity tied to major academic and medical institutions.

Foralumab is currently being evaluated in multiple clinical programs, including non-active secondary progressive multiple sclerosis (na-SPMS), Multiple System Atrophy (MSA), mild Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and Long COVID.

(TLSA) believes this intranasal delivery method may help modulate the immune system while reducing the side effects often associated with traditional systemic antibody therapies. If successful, the platform could have applications across a broad range of neurological and inflammatory disorders.

In addition to foralumab, (TLSA) has previously advanced other immunology and oncology assets, but the company is now primarily focused on expanding the clinical development of its lead intranasal therapy.

With multiple active Phase 2 studies and a differentiated immunotherapy platform, (TLSA) is working to develop a new approach to treating diseases where inflammation plays a central role in progression.

A Multi-Bil-Dollar Neurology Market Still Searching For Better Options

The global multiple sclerosis treatment market is projected to approach $38B by 2030, yet one of the fastest-progressing forms of the disease continues to face limited treatment options.

Non-active Secondary Progressive Multiple Sclerosis (na-SPMS) affects patients after progression from relapsing-remitting MS, with roughly one-quarter of patients eventually transitioning into the more disabling stage of the disease.

Despite the scale of the market, there are currently no widely effective FDA-approved therapies specifically targeting the non-relapsing subset of SPMS.

The commercial potential surrounding neuroinflammatory disease remains substantial. Roche’s Ocrevus, one of the leading therapies in the space, generated more than $9.1B in global sales, highlighting the size of the category.

At the same time, safety concerns continue to shape the competitive landscape.

In late 2025, a CNS-penetrant therapy candidate from another developer faced an FDA rejection tied to liver toxicity concerns despite reporting positive efficacy data.

That outcome has renewed attention around emerging therapies that may offer differentiated safety and delivery profiles.

The Clinical Developments Driving New Attention Toward (TLSA)

Positive Multiple Sclerosis Data: The company reported new data showing clinically meaningful fatigue improvements in patients with non-active secondary progressive multiple sclerosis.

Early MSA Imaging Results: Tiziana announced initial Phase 2 imaging data showing reductions in PET-measured brain inflammation in the first two Multiple System Atrophy patients.

Phase 2 Alzheimer’s Program Underway: The company is actively advancing a Phase 2 study in mild Alzheimer’s disease.

Expanded Pipeline Across Multiple Conditions: Additional programs are underway in ALS and Long COVID.

Recent Financing Added Capital: In January 2026, the company completed an $8.8M registered direct offering.

Analyst Target Increased: Recent third-party reports indicate that Lucid Capital Markets raised its 12-month target to $9.00.

7 Reasons Why (TLSA) Is Topping Our Watchlist This Morning - Friday, May 22, 2026

Analyst Target Raised: Lucid Capital Markets recently increased its 12-month target from $8 to $9.
Technical Momentum Building: Shares continue trending above the 5, 20, 50, and 100-day moving averages, according to Barchart data.
Two Clinical Updates In One Week: New developments recently emerged across both the na-SPMS and MSA programs.
Encouraging MS Findings: 9 of 14 patients in the Expanded Access na-SPMS program showed at least a 4-point MFIS improvement.
Early Brain Imaging Signals: PET imaging from the MSA Phase 2a study showed reductions in SUV and SUVR across multiple disease-relevant brain regions.
Top-Tier Research Participation: The ongoing na-SPMS study includes institutions such as Harvard, Yale, Johns Hopkins, and Cornell.
Strong Ca-sh Position: The company previously reported approximately $12M in ca-sh with zero debt as of January 2026.

Take A Quick Look At (TLSA) Right Now…

With analyst targets recently moving higher, multiple clinical developments emerging within the same week, encouraging early imaging and fatigue-related findings, and ongoing participation from several leading academic institutions, (TLSA) is beginning to build momentum across the neuroinflammation space.

Add in active Phase 2 programs, continued data visibility heading deeper into 2026, and a balance sheet carrying approximately $12M in ca-sh with zero debt, and the story has become increasingly difficult to ignore.

That is why (TLSA) has moved toward the top of our watchlist today.

We’ll be monitoring (TLSA) closely throughout the session.

Take a closer look while the story continues developing.

And keep an eye on your inbox, our next update could arrive sooner than expected.

Sincerely,
Tate Remington
Chief Editor, Market Maven Insights

^{MarketMavenInsights.com}^{(“MarketMavenInsights” or “MMI”) is owned by Source Coastal Media LLC, a multi member limited liability company. Data is provided from third-party sources and MMI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MMI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors.}

^{Pursuant to an agreement between Source Coastal Media LLC and TD Media LLC, Source Coastal Media LLC has been hired for a period beginning on 05/22/2026 and ending on 05/22/2026 to publicly disseminate information about (TLSA:US) via digital communications. Under this agreement, TD Media LLC has paid Source Coastal Media LLC seven thousand five hundred USD (“Funds”). These Funds were part of the forty seven thousand five hundred USD funds that TD Media LLC received from a third party named Sica Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.}

^{Neither Source Coastal Media LLC, TD Media LLC and their member own shares of (TLSA:US).}

^{Please see important disclosure information here:}^{https://marketmaveninsights.com/disclosure/tlsa-vconj/#details}